niacinamide has been researched along with Thymus Neoplasms in 14 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells." | 7.79 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells." | 3.79 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus." | 1.38 | Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. ( Luyken, J; Neuhaus, T, 2012) |
| "Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective." | 1.35 | Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. ( Bisagni, G; Boni, C; Cavazza, A; Gardini, G; Rossi, G; Sartori, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sajithlal, GB | 1 |
| Hamed, HA | 1 |
| Cruickshanks, N | 1 |
| Booth, L | 1 |
| Tavallai, S | 1 |
| Syed, J | 1 |
| Grant, S | 1 |
| Poklepovic, A | 1 |
| Dent, P | 1 |
| Pagano, M | 1 |
| Sierra, NM | 1 |
| Panebianco, M | 1 |
| Rossi, G | 3 |
| Gnoni, R | 1 |
| Bisagni, G | 2 |
| Boni, C | 2 |
| Simonelli, M | 1 |
| Zucali, PA | 2 |
| Suter, MB | 1 |
| Lorenzi, E | 1 |
| Rubino, L | 1 |
| Fatuzzo, G | 1 |
| Alloisio, M | 1 |
| Santoro, A | 2 |
| Bolzacchini, E | 1 |
| Chini, C | 1 |
| Pinotti, G | 1 |
| Li, XF | 1 |
| Chen, Q | 1 |
| Huang, WX | 1 |
| Ye, YB | 1 |
| Azad, A | 1 |
| Herbertson, RA | 1 |
| Pook, D | 1 |
| White, S | 1 |
| Mitchell, PL | 1 |
| Tebbutt, NC | 1 |
| Cavazza, A | 2 |
| Sartori, G | 2 |
| Gardini, G | 1 |
| Dişel, U | 1 |
| Oztuzcu, S | 1 |
| Beşen, AA | 1 |
| Karadeniz, C | 1 |
| Köse, F | 1 |
| Sümbül, AT | 1 |
| Sezer, A | 1 |
| Nursal, GN | 1 |
| Abalı, H | 1 |
| Ozyılkan, O | 1 |
| Force, J | 1 |
| Rajan, A | 1 |
| Dombi, E | 1 |
| Steinberg, SM | 2 |
| Giaccone, G | 2 |
| Schirosi, L | 1 |
| Nannini, N | 1 |
| Nicoli, D | 1 |
| Valli, R | 1 |
| Buti, S | 1 |
| Garagnani, L | 1 |
| Calabrese, F | 1 |
| Marchetti, A | 1 |
| Buttitta, F | 1 |
| Felicioni, L | 1 |
| Migaldi, M | 1 |
| Rea, F | 1 |
| Di Chiara, F | 1 |
| Mengoli, MC | 1 |
| Petrini, I | 1 |
| Meltzer, PS | 1 |
| Luo, J | 1 |
| Lee, C | 1 |
| Lee, HS | 1 |
| Killian, KJ | 1 |
| Wang, Y | 2 |
| Tsokos, M | 1 |
| Roncalli, M | 1 |
| Neuhaus, T | 1 |
| Luyken, J | 1 |
| Bartoli, GM | 1 |
| Piccioni, E | 1 |
| Agostara, G | 1 |
| Calviello, G | 1 |
| Palozza, P | 1 |
| Fishman, M | 1 |
| Essani, N | 1 |
| Costlow, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort[NCT03921671] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | ||
| Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)[NCT03449173] | Phase 2 | 56 participants (Anticipated) | Interventional | 2017-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Thymus Neoplasms
| Article | Year |
|---|---|
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase In | 2015 |
1 trial available for niacinamide and Thymus Neoplasms
| Article | Year |
|---|---|
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large | 2011 |
12 other studies available for niacinamide and Thymus Neoplasms
| Article | Year |
|---|---|
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 C | 2013 |
Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Topics: Aged; Antineoplastic Agents; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; N | 2014 |
Response of Malignant Thymoma to Sorafenib.
Topics: Adult; Antineoplastic Agents; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thymoma; | 2016 |
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; | 2009 |
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Topics: Base Sequence; Benzenesulfonates; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Miss | 2009 |
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Female; Humans; Middle Aged; Niacinamide; Phenylure | 2011 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumo | 2012 |
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Protein | 2012 |
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged | 2012 |
Different mechanisms of tert-butyl hydroperoxide-induced lethal injury in normal and tumor thymocytes.
Topics: Adenosine Triphosphate; Animals; Cell Compartmentation; Cell Survival; Cells, Cultured; Cytosol; Def | 1994 |
TPA induction of EL4 resistance to macrophage-released TNF: role of ADP-ribosylation in tumoricidal activities of TNF and other factors.
Topics: Animals; Antibodies; Benzamides; Calcimycin; Cytotoxicity, Immunologic; Cytotoxins; Down-Regulation; | 1990 |